Get the Stockscreener App
297.69
0.29%
1.176
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $297.69, with a volume of 903.76K.
It is up +0.29% in the last 24 hours and up +8.12% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$296.51
Open:
$295.07
24h Volume:
903.76K
Relative Volume:
0.52
Market Cap:
$57.89B
Revenue:
$328.68B
Net Income/Loss:
$2.55B
P/E Ratio:
22.84
EPS:
13.0349
Net Cash Flow:
$1.56B
1W Performance:
+5.58%
1M Performance:
+8.12%
6M Performance:
-14.10%
1Y Performance:
+0.38%
1-Day Range:
$292.50
$297.68
1-Week Range:
$278.51
$297.52
52-Week Range:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
297.56 | 55.06B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
785.89 | 88.46B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
235.93 | 55.64B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
86.49 | 9.51B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.51 | 1.28B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-22-26 | Upgrade | Jefferies | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora announces Q3 FY26 earnings release date - scanx.trade
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release - FinancialContent
Cencora Inc. focuses on pharmaceutical distribution and healthcare services - AD HOC NEWS
Cencora CubixxCT from Cencora Inc.cold-chain automation for hospital pharmacies - AD HOC NEWS
Form 4 Cencora Inc For: 30 June By Investing.com - Investing.com Canada
Cencora (COR) CFO receives 21,304 restricted stock units vesting through 2029 - Stock Titan
Cencora (COR) CFO files Form 3 showing small direct and trust holdings - Stock Titan
Cencora Pick of the Week at Smart Insider Following Chairman's Share Purchase - marketscreener.com
Cencora reports steady business model, shares anchored in US healthcare distribution - AD HOC NEWS
Cencora, Inc. (COR) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
The Velocity patient support solution from Cencora Inc.integrated care for specialty therapies - AD HOC NEWS
Cencora Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cencora operations and strategy, shares reflect ongoing integration of COR acquisition - AD HOC NEWS
Cencora (COR) Stock After Recent Pullback And DCF Valuation Gap - Yahoo Finance
Nucleus inventory solution from Cencora Inc.modular cabinets and tighter control for specialty pr - AD HOC NEWS
Cencora (COR) Launches Nucleus Pilot As Verizon Executive Joins As CHRO - Yahoo Finance
Cencora revises 2026 outlook, shares underpinned by buyback and analyst support - Ad-hoc-news.de
Knights of Columbus Large Cap Value Fund's Cencora Inc(COR) Holding History - GuruFocus
Cencora, S&P 500 peer under pressure, shares lag broader healthcare distributors - Ad-hoc-news.de
3 Big Reasons to Love Cencora (COR) - Yahoo Finance
Cencora (COR) Stock After Healthcare Supply Chain Reassessment Is The Market Overreacting - simplywall.st
Price to sales forward of Cencora, Inc. – NYSE:COR - TradingView
Cencora adjusts amid healthcare shifts, shares trade steadily on NYSE - Ad-hoc-news.de
Enterprise value to revenue forward of Cencora, Inc. – LS:766149 - TradingView
Enterprise value to EBIT forward of Cencora, Inc. – NYSE:COR - TradingView
Cencora, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh - TradingView
AQR Trend Total Return Fund's Cencora Inc(COR) Holding History - GuruFocus
Cencora, Inc. Actuals & Estimates (NYSE:COR) - TradingView
Enterprise value to EBIT forward of Cencora, Inc. – LS:766149 - TradingView
COR Forecast — Price Target — Prediction for 2027 - TradingView
Cencora analyst targets imply upside, shares in S&P 500 healthcare focus - Ad-hoc-news.de
Cencora raises earnings outlook on share repurchases - MSN
Cencora (COR) Q2 2026 Earnings Call Transcript - Fortune
Price to earnings forward of Cencora, Inc. – NYSE:COR - TradingView
Price to earnings forward of Cencora, Inc. – LS:766149 - TradingView
Centene Corp updates home health strategy, shares tracked against managed care peers - Ad-hoc-news.de
Cencora (COR) Launches Nucleus Pilot And Names A New HR Chief - Sahm
Cencora Inc (COR) Institutional Confidence - TradingKey
Price to book forward of Cencora, Inc. – LS:766149 - TradingView
Insider Buying: Lauren Tyler Acquires Shares of Cencora Inc (COR) - GuruFocus
Are Wall Street analysts bullish on Cencora stock? - MSN
Cencora (COR) director Lauren M. Tyler buys 550 shares in open market - Stock Titan
Argus Adjusts Price Target on Cencora to $340 From $4000, Maintains Buy Rating - Moomoo
BofA Adjusts Price Target on Cencora to $285 From $280 - marketscreener.com
Cencora Inc (COR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
A Look at Cencora Inc (COR) After 3.6% Gain -- GF Value $291.84 vs Price $281.10 - GuruFocus
Cencora insider buying draws attention, shares trade higher on NYSE - Ad-hoc-news.de
Cencora Inc (COR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Insider Buying: Dermot Durcan Acquires Additional Shares of Cenc - GuruFocus
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks By Investing.com - Investing.com Australia
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cencora Inc Stock (COR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DURCAN DERMOT MARK | Director |
Jun 18 '26 |
Buy |
274.19 |
4,000 |
1,096,760 |
31,767 |
| DURCAN DERMOT MARK | Director |
May 28 '26 |
Buy |
266.26 |
4,000 |
1,065,040 |
27,767 |
| Battaglia Silvana | Executive Vice President |
Mar 11 '26 |
Option Exercise |
0.00 |
8,415 |
0 |
27,239 |
| Campbell Elizabeth S | Executive Vice President |
Mar 11 '26 |
Option Exercise |
0.00 |
12,623 |
0 |
36,548 |
| Cleary James F | Chief Financial Officer |
Mar 11 '26 |
Option Exercise |
0.00 |
12,623 |
0 |
165,766 |
| Mauch Robert P. | President & CEO |
Feb 20 '26 |
Option Exercise |
86.09 |
3,762 |
323,871 |
69,155 |
| Mauch Robert P. | President & CEO |
Feb 20 '26 |
Sale |
358.94 |
3,762 |
1,350,332 |
65,393 |
| Mauch Robert P. | President & CEO |
Feb 18 '26 |
Sale |
359.46 |
1,333 |
479,160 |
65,393 |
1.47%
2.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):